Hims & Hers Health, Inc. (HIMS)
Market Cap | 11.25B |
Revenue (ttm) | 2.01B |
Net Income (ttm) | 193.60M |
Shares Out | 226.02M |
EPS (ttm) | 0.79 |
PE Ratio | 63.11 |
Forward PE | 68.49 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 74,604,125 |
Open | 57.12 |
Previous Close | 59.15 |
Day's Range | 49.60 - 57.45 |
52-Week Range | 18.33 - 72.98 |
Beta | 2.25 |
Analysts | Hold |
Price Target | 37.20 (-25.27%) |
Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $37.2, which is a decrease of -25.27% from the latest price.
News

Why Hims & Hers stock is failing to retain menopause gains and what comes next?
Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments – a large and underserved market. However, the rally is fading...

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem
Hims & Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this ...

Hims & Hers: Ramping Up A New Billion-Dollar Segment (Rating Upgrade)
I am upgrading Hims & Hers Health, Inc. to a Buy with an $80 price target, implying 30% upside. The new 'Hers' specialty in Menopause is expected to help the company drive over $1B in Hers segment rev...

How HIMS Stock Rises To $120?
Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Weight-loss drugs shook up the stock market. Menopause treatments could be next.
Hims & Hers is taking aim at menopause and perimenopause in an attempt to tap in to a huge and potentially highly lucrative market.

Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women's health, offering access to aff...

Hims & Hers to Offer Treatments for Menopause, Perimenopause
Hims & Hers Health said it is now providing menopause care, marking the company's latest push into hormone-replacement therapies.

Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results...

Hims & Hers: Why I'm Betting On HIMS Heading To $100
I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aimi...
How Hims & Hers founder Joe Spector turned 10 failures into $1B idea
Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite podcast. How do you break into a tough market and win?

Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor's Office
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today published a new white paper - Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety - detailing how...

Hims & Hers Looks To Close $10 ARPU Gap With Product Expansion And Partnerships
Hims & Hers is driving growth through holistic treatment plans, strategic pharma partnerships, and expanded prescription offerings to boost revenue per subscriber. HIMS' recent partnership with Marius...

Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
PHILADELPHIA , Oct. 3, 2025 /PRNewswire/ -- Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) ...

Buy HIMS Stock At $56?
Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primaril...

Hims & Hers: Growth Meets FDA Scrutiny And Tariff Risks
Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuatio...

Hims & Hers Powers YieldMax's Latest Options-Based Income ETF
YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).

Hims & Hers Health: Bumpy Ride Will End
Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scruti...

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims
The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding they co...

FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs
The Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” about s...

Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims
Hims & Hers Health Inc. (NYSE: HIMS) saw its stock fall 6% on Tuesday following the release of a warning letter from the US Food and Drug Administration (FDA) concerning marketing claims related to it...

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
Hims & Hers Health Inc. HIMS stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept.

US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs
The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatmen...

US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules
U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement breached federal law as it highlighted the benefits of weight-loss drugs without ...

Hims & Hers Looks Like Hyper Growth At A Reasonable Price
Hims is now a GARP stock, combining rapid revenue and subscriber growth with a lower, fair valuation after a recent selloff. The company's scalable model, product launches, and global expansion plans ...